위더스제약

330350KOSDAQ의약품 제조업

46.5 / 100

Reference Date: 2026-06-10

Financial Score22.0 / 40

News Sentiment12.5 / 25

Momentum2.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit is on a declining trend. Plunged 24.5% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Widus Pharmaceutical is a pharmaceutical company specializing in finished drug products for chronic diseases, focusing on cardiovascular, musculoskeletal, and digestive system treatments. Its key revenue driver is Atoren, a generic version of Lipitor, accounting for about 30% of total sales. The company is expanding its CMO business and enhancing market share through new product development.

Number of Employees

220people

Average Salary

52.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

17.25Industry Average 11.933.0Point

Higher than industry avg (caution)

PBR

0.87Industry Average 0.894.0Point

In line with industry avg

ROE

5.20Industry Average 4.014.0Point

In line with industry avg

Debt Ratio

5.90Industry Average 12.436.5Point

Half of industry avg (excellent)

Trend 2023~20254.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲15.9% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼14.2% (2-year basis)

ROE Trend

2.0 / 4

Avg ROE 6.5% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (2%, downtrend)

Current 6,490Won52-week high 11,94052-week low 6,340

1-month return0.0Point

1m -24.53% (strong drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral분기보고서 (2026.03)2026-05-15